Curis Inc (CRIS) has issued an announcement.
Curis, Inc. has revealed promising updated data from its TakeAim Leukemia study, which will be showcased at upcoming ASCO and EHA conferences. This data pertains to 25 new patients with specific genetic mutations in Acute Myelogenous Leukemia, who were treated with the drug emavusertib. The announcement underscores Curis’s ongoing efforts to innovate in cancer therapy, though the company cautions that forward-looking statements are subject to various risks and uncertainties that may affect its operations and results.
For a thorough assessment of CRIS stock, go to TipRanks’ Stock Analysis page.
